{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:44:10Z","timestamp":1776721450335,"version":"3.51.2"},"reference-count":38,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Reparixin, an anti\u2010inflammatory drug that inhibits interleukin 8 (IL\u20108) activity, might be life\u2010saving for high\u2010risk in\u2010hospital patients without increasing the risk of infection according to a previous meta\u2010analysis. With the increasing availability of randomised data the aim of the current study is to update previous findings by including any randomised control trials (RCTs) investigating the impact of reparixin on survival of critically ill or transplant patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A search strategy was developed to identify all RCTs involving reparixin in critically ill or transplant patients, with the exclusion of oncological patients. Two trained and independent authors conducted a thorough search of relevant databases. In addition, backward snowballing was employed. Language restrictions were not imposed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our analysis included a total of nine studies involving 733 patients: 437 received reparixin and 296 the comparator. The reparixin group had a significantly lower all\u2010cause mortality rate compared to the control group [15\/437 (3.4%) vs. 19\/294 (6.4%), odds ratio\u2009=\u20090.47 (95% confidence interval 0.23\u20130.96), <jats:italic>p<\/jats:italic>\u2010value for effect .04, I2\u2009=\u200922%, number needed to treat\u2009=\u200933]. These findings had the same direction and magnitude of effect across COVID\u201019 patients (<jats:italic>n<\/jats:italic>\u2009=\u2009325) and non\u2010COVID\u201019 patients (<jats:italic>n<\/jats:italic>\u2009=\u2009408). Furthermore, there were no significant differences in the rate of pneumonia, sepsis or non\u2010serious infections between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The findings of this meta\u2010analysis indicate that reparixin, an anti\u2010inflammatory drug, improved survival in critically ill or transplant patients (including both COVID\u201019 and non\u2010COVID\u201019 patients) without increasing the risk of infection.<\/jats:p><\/jats:sec>","DOI":"10.1111\/eci.14015","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T02:39:11Z","timestamp":1683772751000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Reparixin improves survival in critically ill and transplant patients: A <scp>meta\u2010analysis<\/scp>"],"prefix":"10.1111","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5906-9235","authenticated-orcid":false,"given":"Gioia","family":"Piersanti","sequence":"first","affiliation":[{"name":"Department of Anesthesia and Intensive Care IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8594-5980","authenticated-orcid":false,"given":"Giovanni","family":"Landoni","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care IRCCS San Raffaele Scientific Institute  Milan Italy"},{"name":"Faculty of Medicine Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Scquizzato","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Zangrillo","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Intensive Care IRCCS San Raffaele Scientific Institute  Milan Italy"},{"name":"Faculty of Medicine Vita\u2010Salute San Raffaele University  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-2198","authenticated-orcid":false,"given":"Lorenzo","family":"Piemonti","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Vita\u2010Salute San Raffaele University  Milan Italy"},{"name":"Diabetes Research Institute IRCCS San Raffaele Scientific Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20141813"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01023"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-844530"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02590-2017"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000001467"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2017.07.005"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2022.101536"},{"key":"e_1_2_8_9_1","volume-title":"StatPearls [Internet]","author":"Chakraborty RK","year":"2022"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2026131"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.806462"},{"key":"e_1_2_8_12_1","volume-title":"Surgical Treatment: Evidence\u2010Based and Problem\u2010Oriented","author":"Marshall JC","year":"2001"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201129"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab437"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023656"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.932251"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00644-6"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2022.2135"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01499-z"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-020-0824-3"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01749.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2748"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1243-8"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_8_25_1","unstructured":"ClinicalTrial.gov NCT02370238.A Double\u2010Blind Study of Paclitaxel in Combination with Reparixin or Placebo for Metastatic Triple\u2010Negative Breast Cancer (FRIDA).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02370238."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/039463200702000104"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/09636897211001774"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1480"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2007.11.417"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12488"},{"key":"e_1_2_8_31_1","unstructured":"ClinicalTrial.gov NCT03031470.Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03031470"},{"key":"e_1_2_8_32_1","unstructured":"ClinicalTrial.gov NCT00248040.Reparixin in Prevention of Delayed Graft Function after Kidney Transplantation.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00248040"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16695"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63089"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03364-w"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6252"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2206346"},{"key":"e_1_2_8_38_1","unstructured":"ClinicalTrial.gov NCT05254990.Reparixin 1200 mg TID as add\u2010on to SoC to limit disease progression in hospitalised patients with COVID\u201019 and other community\u2010acquired pneumonia. A Multicentre Randomised Double\u2010Blinded Placebo\u2010Controlled Phase III Trial (REPAVID\u201022)https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05254990"},{"key":"e_1_2_8_39_1","unstructured":"ClinicalTrial.gov NCT05496868.Add\u2010on Reparixin in Adult Patients With ARDS.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05496868"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/eci.14015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T03:43:07Z","timestamp":1694403787000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/eci.14015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/eci.14015"],"URL":"https:\/\/doi.org\/10.1111\/eci.14015","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]},"assertion":[{"value":"2023-03-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14015"}}